keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 324 | 5日内发货 | ||
5 mg | ¥ 538 | 5日内发货 | ||
10 mg | ¥ 813 | 5日内发货 | ||
25 mg | ¥ 1,050 | 5日内发货 | ||
50 mg | ¥ 1,390 | 5日内发货 |
Osimertinib dimesylate 的其他形式现货产品:
产品描述 | Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M). |
靶点活性 | EGFR (L858R/T790M):1 nM, EGFR (L858R):12 nM |
体外活性 | Osimertinib (AZD-9291) shows similar potency to early generation tyrosine kinase inhibitor in inhibiting EGFR phosphorylation in EGFR cells harboring sensitizing EGFR mutants including PC-9 (ex19del), H3255 (L858R) and H1650 (ex19del) (mean IC50s: 13 to 54 nM). Osimertinib also potently inhibits phosphorylation of EGFR in T790M mutant cell lines H1975 (L858R/T790M), PC-9VanR (ex19del/T790M), with mean IC50 potency less than 15 nM [1]. |
体内活性 | The tumor-bearing mice are treated with Osimertinib (5 mg/kg/day) for one to two weeks. Within days of treatment, 5 of 5 C/L858R mice display nearly 80% reduction in tumor volume by magnetic resonance imaging MRI after therapy with Osimertinib, while 5 of 5 mice treated with vehicle shows tumor growth [1]. Upon dosing Osimertinib in three efficacy models, comparable efficacy is observed at relatively low doses (10 mg/kg per day). The excellent efficacy is also observed when Osimertinib is dosed at 5 mg/kg per day [2]. |
别名 | 奥希替尼二甲磺酸盐, Mereletinib (dimesylate), AZD-9291 (dimesylate) |
分子量 | 691.82 |
分子式 | C30H41N7O8S2 |
CAS No. | 2070014-82-1 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 0.4 mg/mL (0.58 mM), Sonication and heating are recommended.
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Osimertinib dimesylate 2070014-82-1 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Osimertinib Dimesylate AZD 9291 奥希替尼二甲磺酸盐 Osimertinib Mereletinib Mereletinib (dimesylate) AZD-9291 (dimesylate) AZD9291 AZD-9291 Inhibitor inhibitor inhibit